Immatics N.V Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-0.8%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$2.24next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 12 Nov 2026 |
| Full Year 2026 Financial Results and Business Update | 4 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents (including other financial assets) Quarterly521.5MTarget: Sufficient to fund operations into 2028
anzu-cel (IMA203) Confirmed Objective Response Rate (cORR) in Advanced Melanoma Annually5,600.0%Target: Maintain competitive efficacy profile vs standard of care
IMA203CD8 (GEN2) Confirmed Objective Response Rate (cORR) in Gynecologic Cancers Annually6,300.0%Target: Establish proof-of-concept in hard-to-treat solid tumors
Watch Items
- Phase 3 SUPRAME trial interim and final analysis triggers for anzu-celTrigger: Expected to be triggered in late 2026Action: Prepare Biologics License Application (BLA) submission for 1H 2027
- IMA402 PRAME Bispecific Recommended Phase 2 Dose (RP2D) determinationTrigger: Expected in 2H 2026Action: Initiate additional Phase 1b expansion cohorts in monotherapy and combination settings
- IMA401/IMA402 Bispecific Combination Phase 1 trial initiation in sqNSCLCTrigger: First patient dosed in mid-to-late 2026Action: Monitor safety, tolerability, and initial synergistic anti-tumor activity
Research as of 20 Jun 2026